Evidence for/Against Administration of Fibrinogen Concentrate and Coagulation Factor Concentrate During an Obstetrical Hemorrhage

  • Michael DombrowskiEmail author
  • Michael Paidas


Correction of hypofibrinogenemia is increasingly being recognized as an important component of treatment of obstetric hemorrhage. Fibrinogen levels below 2 g/L are predictive of severe hemorrhage. Fibrinogen concentrate is an attractive means of fibrinogen replacement and has advantages over both fresh frozen plasma and cryoprecipitate. Data are beginning to emerge supporting the use of fibrinogen concentrate in the obstetric population, especially when guided by thromboelastometry/thromboelastography-driven protocols. Prevention of clot breakdown via use of antifibrinolytic therapy is an important component as well.


Fibrinogen concentrate Thromboelastometry Thromboelastography Postpartum hemorrhage 


  1. 1.
    Sørensen B, Tang M, Larsen OH, Laursen PN, Fenger-Eriksen C, Rea CJ. The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding. Thromb Res. 2011;128:S13–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007;5:266–73.CrossRefPubMedGoogle Scholar
  3. 3.
    de Lloyd L, Bovington R, Kaye A, Collis RE, Rayment R, Sanders J, Rees A, Collins PW. Standard haemostatic tests following major obstetric haemorrhage. Int J Obstet Anesth. 2011;20:135–41.CrossRefPubMedGoogle Scholar
  4. 4.
    Wikkelso AJ, Edwards HM, Afshari A, et al. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. Br J Anaesth. 2015;114:623–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Ducloy-Bouthors A-S, Mignon A, Huissoud C, Grouin J-M, Mercier FJ. Fibrinogen concentrate as a treatment for postpartum haemorrhage-induced coagulopathy: a study protocol for a randomised multicentre controlled trial. The fibrinogen in haemorrhage of DELivery (FIDEL) trial. Anaesth Crit Care Pain Med. 2016;35:293–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Collins RE, Collins PW. Haemostatic management of obstetric haemorrhage. Anaesthesia. 2015;70(Supp 1):78–86.CrossRefPubMedGoogle Scholar
  7. 7.
    Ahmed S, Harrity C, Johnson S, et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage—an observational study. Transfus Med. 2012;22:344–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus. 2012;10:23–7.PubMedPubMedCentralGoogle Scholar
  9. 9.
    US Package Insert for RiaSTAP, CSL Behring, January 2009.Google Scholar
  10. 10.
    Solomon C, Groner A, Ye J, Pendrak I. Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data. Thromb Haemost. 2015;113(4):759–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Fenger-Eriksen C, Ingerslev J, Sørensen B. Fibrinogen concentrate—a potential universal hemostatic agent. Expert Opin Biol Ther. 2009;9:1325–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Costa-Filho R, Hochleitner G, Wendt M, Teruya A, Spahn DR. Over 50 years of fibrinogen concentrate. Clin Appl Thromb. 2016;22:109–14.CrossRefGoogle Scholar
  13. 13.
    Jensen NHL, Stensballe J, Afshari A. Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review. Acta Anaesthesiol Scand. 2016;60:1033–42.CrossRefPubMedGoogle Scholar
  14. 14.
    Okerberg CK, Williams LA, Kilgore ML, et al. Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients—an economic evaluation. Vox Sang. 2006;111:292–8.CrossRefGoogle Scholar
  15. 15.
    Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev. 2016;(8):CD007871. doi:
  16. 16.
    Glynn JC, Plaat F. Prothrombin complex for massive obstetric haemorrhage. Anaesthesia. 2007;62:202–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Ducloy-Bouthors AS, Duhamel A, Kipnis E, et al. Postpartum haemorrhage related early increase in D-dimers is inhibited by tranexamic acid: haemostasis parameters of a randomized controlled open labelled trial. Br J Anaesth. 2016;116:641–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Antony K, Mansouri R, Arndt M, Rocky Hui S-K, Jariwala P, Mcmullen V, Teruya J, Aagaard K. Establishing thromboelastography with platelet-function analyzer reference ranges and other measures in healthy term pregnant women. Am J Perinatol. 2015;32:545–54.CrossRefPubMedGoogle Scholar
  19. 19.
    Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. Anaesthesia. 2015;70:166–75.CrossRefPubMedGoogle Scholar
  20. 20.
    Collins PW, Cannings-John R, Bruynseels D, Mallaiah S, Dick J, Elton C, Weeks AD, Sanders J, Aawar N, Townson J, Hood K, Hall JE, Collis RE. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. Br J Anaesth. 2017;119:411–21. Scholar
  21. 21.
    Collins PW, Cannings-John R, Bruynseels D, Mallaiah S, Dick J, Elton C, Weeks A, Sanders J, Aawar N, Townson J, Hood K, Hall J, Harding K, Gauntlett R, Collis R, OBS2 Study Collaborators. Viscoelastometry guided fresh frozen plasma infusion for postpartum haemorrhage: OBS2, an observational study. Br J Anaesth. 2017;119:422–34. Scholar
  22. 22.
    Collins P, Abdul-Kadir R, Thachil J, The Subcommittees on Women’ s Health Issues in Thrombosis and Haemostasis and on Disseminated Intravascular Coagulation. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:205–10.CrossRefPubMedGoogle Scholar
  23. 23.
    Paidas M, Hossain N. Unexpected postpartum hemorrhage due to an acquired factor VIII inhibitor. Am J Perinatol. 2013;31:645–54.CrossRefPubMedGoogle Scholar
  24. 24.
    Hossain N, Shamsi T, Haider S, et al. Use of recombinant activated factor VII for massive postpartum hemorrhage. Acta Obstet Gynecol Scand. 2007;86:1200–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Lavigne-Lissalde G, Aya AG, Mercier FJ, et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. J Thromb Haemost. 2015;13:520–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Armstrong S, Fernando R, Ashpole K, Simons R, Columb M. Assessment of coagulation in the obstetric population using ROTEM® thromboelastometry. Int J Obstet Anesth. 2011;20:293–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Schjoldager BTBG, Mikkelsen E, Lykke MR, Præst J, Hvas A-M, Heslet L, Secher NJ, Salvig JD, Uldbjerg N. Topical application of recombinant activated factor VII during cesarean delivery for placenta previa. Am J Obstet Gynecol. 2017;216:608.e1–5. Scholar
  28. 28.
    Shakur H, Roberts I, Fawole B, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389:2105–16. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Section of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive SciencesYale School of Medicine, Yale Women and Children’s Center for Blood Disorders and Preeclampsia AdvancementNew HavenUSA

Personalised recommendations